NEW DRUG IN THE EVOLUTION OF LONG-ACTING INSULINS
https://doi.org/10.21518/2079-701X-2017-20-160-165
Abstract
Insulin glargine, synthesized using recombinant DNA technology in a concentration of 100 U/ml, was the first once-daily longacting insulin analogue introduced into clinical practice in 2000. Glargin has a well-established record of efficacy and safety and is the most widely used insulin worldwide. In February 2015, the drug lost its US patent protection, which opened the door for biosimilar competitors.
About the Authors
I. V. Kononenko
Endocrinology Research Center of the Ministry of Health of Russia; Sechenov First Moscow State Medical University.
Russian Federation
Russian Federation
PhD in medicine.
Moscow.
O. M. Smirnova
Endocrinology Research Center of the Ministry of Health of Russia; Sechenov First Moscow State Medical University.
Russian Federation
Russian Federation
MD, Prof.
Moscow.
References
1. Сахарный диабет. Диагностика, лечение, профилактика. Под редакцией И.И. Дедова, М.В. Шестаковой. МИА, Москва, 2011.
2. Инсулинотерапия. Пособие для врачей. Под редакцией И.И. Дедова. Москва, 2003.
3. Bolli GB, Owens DR. Insulin glargine. Lancet, 2000, 356: 443-445.
4. Rosenstock J, Dailey G, Massi-Benedetti M et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care, 2005, 28: 950-955.
5. Lamos EM, Younk LM, Davis SN. Concentrated insulins: the new basal insulins. Therapeutics and Clinical Risk Management, 2016, 12: 389-400.
6. Wang F, Zassman S, Goldberg PA. rDNA insulin glargine U300 – a critical appraisal. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2016, 9: 425-441.
7. New insulin Glargin 300U/ml for the treatment of type I and type 2 Diabetes mellitus. Jennifer Goldman and John R White. Annals of Pharmacolotherapy, 2015, 49(10): 1153-1161.
8. Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, Riddle MC. New Insulin Glargine 300Units/mL versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). Diabetes Care, 2015, 38: 22172225. DOI: 10.2337/dc15-0249.
9. Matsuhisa M, Koyama M, Cheng X, Shimizu S, Hirose T, on behalf of the EDITION JP 1 study group. New insulin glargine 300 U/mL: glycaemic control and hypoglycaemia in Japanese people with type 1 diabetes mellitus (EDITION JP 1). 50th Annual meeting of the European Association for the Study Diabetes, Vienna, Austria, 15–19 September 2014. 2014: Abstract 975.
10. Дедов И.И., Шестакова М.В., Галстян Г.Р. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом (7-й вып.). Сахарный диабет, 2015, 18(1S): 1–112.
11. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF and Paul SK, for the 4-T Study Group. Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. N Engl J Med, 2009, 361: 1736-47.
12. Standards of Medical Care in Diabetes. Pharmacologic Approaches to Glycemic Treatment. Diabetes Care, 2017, 40(Suppl. 1): S64–S74. DOI: 10.2337/dc17-S011.
13. Ritzel R, Roussel R, Bolli GB et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes. Metab., 2015, 17(9): 859–867.
14. Riddle MC, Bolli GB, Ziemen M et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care, 2014, 37(10): 2755–2762.
15. Yki-Jarvinen H, Bergenstal R, Ziemen M et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care, 2014, 37(12): 3235–3243.
16. Bolli GB, Riddle MC, Bergenstal RM et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes. Metab., 2015, 17(4): 386–394.
17. Terauchi Y, Koyama M, Cheng X, Shimizu S, Hirose T, on behalf of the EDITION JP 2 study group. Glycaemic control and hypoglycaemia in Japanese people with type 2 diabetes mellitus receiving new insulin glargine 300 U/mL in combination with OADs (EDITION JP 2). 50th Annual meeting of the European Association for the Study Diabetes, Vienna, Austria, 15-19 September 2014. 2014: Abstract 976.
18. Becker RH, Nowotny I, Teichert L et al. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml. Diabetes Obes. Metab., 2015, 17(3): 261–267.
19. Bolli GB and DeVries JH. New Long-Acting Insulin Analogs: From Clamp Studies to Clinical Practice. Diabetes Care, 2015, 38: 541– 543. DOI: 10.2337/dc14-2314.
20. Becker RH, Dahmen R, Bergmann K et al. New insulin glargine 300 Units/mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units/mL-1. Diabetes Care, 2015, 38(4): 637–643.
Review
For citations:
Kononenko IV, Smirnova OM. NEW DRUG IN THE EVOLUTION OF LONG-ACTING INSULINS. Meditsinskiy sovet = Medical Council. 2017;(20):160-165. (In Russ.) https://doi.org/10.21518/2079-701X-2017-20-160-165
Views:
696
Email this article 